309 related articles for article (PubMed ID: 27183910)
1. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
Yahyanejad S; King H; Iglesias VS; Granton PV; Barbeau LM; van Hoof SJ; Groot AJ; Habets R; Prickaerts J; Chalmers AJ; Eekers DB; Theys J; Short SC; Verhaegen F; Vooijs M
Oncotarget; 2016 Jul; 7(27):41251-41264. PubMed ID: 27183910
[TBL] [Abstract][Full Text] [Related]
2. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma.
Hiddingh L; Tannous BA; Teng J; Tops B; Jeuken J; Hulleman E; Boots-Sprenger SH; Vandertop WP; Noske DP; Kaspers GJ; Wesseling P; Wurdinger T
Oncotarget; 2014 Jan; 5(2):363-74. PubMed ID: 24495907
[TBL] [Abstract][Full Text] [Related]
3. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Gilbert CA; Daou MC; Moser RP; Ross AH
Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
[TBL] [Abstract][Full Text] [Related]
4. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
5. Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
Zhang M; Herion TW; Timke C; Han N; Hauser K; Weber KJ; Peschke P; Wirkner U; Lahn M; Huber PE
Neoplasia; 2011 Jun; 13(6):537-49. PubMed ID: 21677877
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
Oancea-Castillo LR; Klein C; Abdollahi A; Weber KJ; Régnier-Vigouroux A; Dokic I
Cancer Biol Ther; 2017 Jun; 18(6):400-406. PubMed ID: 28494176
[TBL] [Abstract][Full Text] [Related]
7. Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
Shields LB; Kadner R; Vitaz TW; Spalding AC
Radiat Oncol; 2013 Apr; 8():101. PubMed ID: 23618500
[TBL] [Abstract][Full Text] [Related]
8. Time trends in glioblastoma multiforme survival: the role of temozolomide.
Dubrow R; Darefsky AS; Jacobs DI; Park LS; Rose MG; Laurans MS; King JT
Neuro Oncol; 2013 Dec; 15(12):1750-61. PubMed ID: 24046259
[TBL] [Abstract][Full Text] [Related]
9. An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Yahyanejad S; van Hoof SJ; Theys J; Barbeau LM; Granton PV; Paesmans K; Verhaegen F; Vooijs M
Radiother Oncol; 2015 Sep; 116(3):467-72. PubMed ID: 26163089
[TBL] [Abstract][Full Text] [Related]
10. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
11. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
[TBL] [Abstract][Full Text] [Related]
12. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Pan E; Mitchell SB; Tsai JS
J Neurooncol; 2008 Jul; 88(3):353-7. PubMed ID: 18389176
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
[TBL] [Abstract][Full Text] [Related]
16. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
[TBL] [Abstract][Full Text] [Related]
20. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
